

1 **TITLE**

2 Accurate Prostate Cancer Detection based on Circulating Tumor Cell Profiling

3

4 **AUTHORS**

5 Sewanti Limaye^a, Simon Chowdhury^b, Nitesh Rohatgi^c, Anantbhusan Ranade^d,

6 Nelofer Syed^e, Johann Riedemann^f, Raymond Page^g, Darshana Patil^h, Dadasaheb

7 Akolkar^h, Vineet Datta^h, Revati Patil^h, Kiran Bendale^h, Pooja Fulmali^h, Pradeep

8 Fulmali^h, Sachin Apurwa^h, Stefan Schusterⁱ, Sudha S Murthy^h, Chirantan Bose^h,

9 Jinumary John^h, Ajay Srinivasan^{h*}, Rajan Datar^h

10

11 **AFFILIATIONS**

12 ^a Sir HN Reliance Foundation Hospital and Research Centre, Mumbai, India

13 ^b Guy's, King's and St. Thomas' Hospital, London, UK

14 ^c Fortis Memorial Research Institute, Gurugram, India

15 ^d Avinash Cancer Clinic, Pune, India

16 ^e John Fulcher Neuro-Oncology Laboratory, Burlington Danes Building,

17 Hammersmith Hospital, Imperial College London, London, UK

18 ^f Cancercare, Parow, Cape Town, South Africa

19 ^g Worcester Polytechnic Institute, Worcester, USA

20 ^h Datar Cancer Genetics, Nasik, India

21 ⁱ Datar Cancer Genetics Europe GmbH, Eckersdorf, Germany

22 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 **CORRESPONDING AUTHOR**

24 Dr. Ajay Srinivasan. E-mail: ajays@datarpgx.org, Phone: +91-253-6690803.

25

26 **KEYWORDS**

27 Prostate Cancer; screening; circulating tumor cells; immunocytochemistry

28

29

30 **ABSTRACT**

31 **Background**

32 Evaluation of serum prostate specific antigen (PSA) is a part of standard prostate
33 cancer diagnostic work-up in symptomatic males as well as for elective prostate
34 cancer screening in asymptomatic males. The low specificity of serum PSA leading
35 to an inability to effectively differentiate prostate cancer from benign prostate
36 conditions is a persistent clinical challenge. Further, the low sensitivity of serum PSA
37 leading to false negatives can miss high-grade / aggressive prostate cancers.

38 **Objective**

39 We describe a non-invasive prostate cancer detection test based on functional
40 enrichment of prostate adenocarcinoma associated circulating tumor cells (PrAD-
41 CTCs) from blood samples and their identification via immunostaining for pan-
42 cytokeratins (PanCK), prostate specific membrane antigen (PSMA), alpha methyl-
43 acyl coenzyme-A racemase (AMACR), epithelial cell adhesion molecule (EpCAM)
44 and common leucocyte antigen (CD45).

45 **Design, Setting, and Participants**

46 The analytical validation studies used VCaP reference prostate cancer cell line to
47 evaluate the performance characteristics of the test. The clinical performance
48 characteristics of the test were first evaluated in a case-control study with 160 known
49 prostate cancer cases and 800 healthy males. A prospective clinical study was
50 performed with samples from 210 suspected cases of prostate cancer.

51 **Outcome Measurements and Statistical Analysis**

52 Analytical validation established analyte stability as well as acceptable performance
53 characteristics. The test showed 100% specificity and 100% sensitivity to
54 differentiate prostate cancer cases from healthy individuals in the case control study

55 and 91.2% sensitivity and 100% specificity to differentiate prostate cancers from
56 benign prostate conditions in the prospective clinical study.

57 **Results and Limitations**

58 The test accurately detects PrAD-CTCs with high sensitivity and specificity
59 irrespective of stage or grade (Gleason score), which translates into low risks of false
60 negatives or overdiagnosis. The test does not detect minor non-adenocarcinoma
61 subtypes of prostate cancer.

62 **Conclusions**

63 The high accuracy of the test offers advantages over PSA based prostate cancer
64 detection.

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80 INTRODUCTION

81 Prostate cancer is globally the second most common malignancy and the seventh
82 highest cause of cancer related mortality among men [1]. Detection of prostate
83 cancer at advanced stages is associated with significant morbidity and mortality as
84 well as reduced survival, while early-stage prostate cancer detection is associated
85 with higher cure rate and improved survival (~99%, 5-year [2]). At present, evaluation
86 of serum prostate specific antigen (PSA) is part of the standard diagnostic work-up in
87 symptomatic cases [3] but less suitable for prostate cancer screening in
88 asymptomatic males due to low specificity [4] and significant risk of false positivity [5]
89 which leads to overdiagnosis and overtreatment [6]. In addition, there is a risk of
90 false negatives, especially in advanced undifferentiated prostate cancers which may
91 have lower PSA levels [7]. More sensitive and specific methods which can provide
92 for more effective prostate cancer detection are required to reduce morbidity and
93 mortality from this disease [8].

94 Circulating tumor analytes in blood have received attention for non-radiological, non-
95 invasive detection of prostate cancer [9]. Apart from serum tumor antigens,
96 circulating tumor nucleic acids have been evaluated for prostate cancer detection but
97 have reported limitations in sensitivity for localized prostate cancer [10]. Circulating
98 tumor cells (CTCs) are viable tumor derived cells in circulation, the molecular and
99 functional evaluation of which may be comparable to that of the tumor tissue from
100 which they originate [11]. CTC evaluations are not prone to the limitations in
101 sensitivity and specificity associated with circulating tumor nucleic acids or serum
102 tumor antigens. Prior studies support the ubiquity of CTCs in prostate cancer,
103 especially in early-stage (localized) disease; disseminated tumor cells (DTCs)
104 released during early stages of prostate cancer are known to remain dormant in the

105 bone marrow and result in metastatic recurrence [12]. In a study of bone marrow
106 aspirates from 533 preoperative prostate cancer cases with localized disease (T2-4,
107 N0), DTCs were detected in 380 cases (71.3%), irrespective of pathologic stage,
108 Gleason grade, or PSA [13]. Another study reported CTCs in 19 (79%) of 24
109 treatment naïve localized prostate cancers [14]. A third study reported >90%
110 sensitivity in 20 known prostate cancer cases and 92.6% sensitivity in 27
111 asymptomatic men undergoing prostate cancer screening [15]. A fourth study on pre-
112 operative blood from 86 prostate cancer cases reported 38.4% - 62.7% CTC
113 detection rates using CellSearch, CellCollector and EPISPOT individually, and
114 80.2% [16] when used together. In a fifth study, using a hybrid microfluidic-imaging
115 along with PSA immunostaining, 38 - 222 CTCs were reported per mL in recently
116 diagnosed cases of localized prostate cancer [17]. In a sixth study, using near-
117 infrared dyes and EpCAM immunostaining, up to 439 CTCs per mL of blood (mean:
118 25 CTCs / mL; median: 10 CTCs / mL) were observed in a cohort of patients with
119 localized prostate cancer [18]. The above studies provide evidence for the biological
120 plausibility of CTC-based prostate cancer screening. Other studies have also shown
121 the inability of existing technology platforms to efficiently enrich and harvest sufficient
122 CTCs. Most prior reports on CTCs in cancer are based on epitope capture using
123 epithelial cell adhesion molecule (EpCAM) followed by immunostaining for
124 cytokeratins (CK). A critical limitation of this approach is its acknowledged inability to
125 effectively enrich and detect CTCs where the expression of target biomarkers such
126 as EpCAM and CK can be significantly lower [19–23] than tumor tissue or reference
127 cell lines. Further, the expression of EpCAM and CK (as well as any other markers)
128 may be even lower in CTCs undergoing epithelial to mesenchymal transition (EMT)
129 [24].

130 We have previously described a functional CTC enrichment process which is
131 immune to the limitations of epitope-based CTC enrichment and yields numerically
132 sufficient CTCs for further applications [25]. We have also shown that CTCs thus
133 enriched from blood of patients with prostate cancer are positive for expression of
134 PSMA and AMACR in addition to EpCAM and PanCK as determined by
135 fluorescence immunocytochemistry (ICC) [26]. This multi-marker CTC profiling has
136 high specificity for adenocarcinomas (AD) which represent the vast majority (~92%)
137 of prostate cancers [27]. The test uses standardized fluorescence intensity (FI)
138 thresholds for detection of marker positive cells, optimized to detect CTCs with a
139 wide range of marker expression, especially those with significantly lower marker
140 expression than tumor cells or reference cell lines. In this manuscript, we report the
141 method development as well as analytical and clinical validation of this test for
142 prostate cancer detection.

143

144 **METHODS**

145 **Study Participants and Samples**

146 Samples for method development, analytical validation and clinical validation studies
147 were obtained from participants in three observational studies, TRUEBLOOD
148 (<http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31879>), ProState
149 (<http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31713>) and RESOLUTE
150 (<http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30733>). The TRUEBLOOD study
151 enrolled known patients with various solid organ cancers or benign (non-malignant)
152 conditions as well as individuals who were suspected of various cancers. The
153 ProState study enrolled known cases of prostate cancers and symptomatic males
154 suspected of prostate cancer. The RESOLUTE study enrolled healthy asymptomatic

155 adults with no prior diagnosis of cancer, no current symptoms or findings suspected
156 of cancer. All studies were approved by the Ethics Committees of the participating
157 institutes and the sponsor and were performed in accordance with the Declaration of
158 Helsinki. Fifteen millilitres of peripheral blood were collected from all enrolled study
159 participants in EDTA vacutainers after obtaining written informed consent. Where
160 possible, tissue samples were also obtained from TRUEBLOOD and ProState study
161 participants referred for a biopsy as per Standard of Care (SoC). In addition, blood
162 samples for research were collected, after obtaining consent, from healthy
163 (asymptomatic) volunteers as well as recently diagnosed or suspected cancer
164 patients who were not a part of either of the above studies but had availed of the
165 sponsor's services. Blood samples from suspected cases of cancers were collected
166 prior to the patients undergoing an invasive biopsy. All biological samples were
167 stored at 2°C - 8°C during transport to reach the clinical laboratory within 46 h.
168 Samples used for clinical validation studies were identity masked by using blood
169 collection vacutainers with a 10-digit alphanumeric code. Identity masking minimized
170 potential biases resulting from differences in sample processing or interpretation of
171 results that could have arisen due to operator's knowledge of the sample. All
172 samples were processed at the CAP and CLIA accredited facilities of the Study
173 Sponsor, which also adhere to quality standards ISO 9001:2015, ISO 27001:2013
174 and ISO 15189:2012.

175

176 **Isolation of Primary Tumor Derived Cells**

177 The isolation of primary tumor derived cells (TDCs) from an excised tumor
178 (malignant / benign) was performed as described previously [25] and is also
179 explained in **Supplementary Materials**.

180

181 **Enrichment of Circulating Tumor Cells from Peripheral Blood**

182 Blood samples (5 mL) were processed for the enrichment of CTC from peripheral
183 blood mononuclear cells (PBMC) as described previously [26,28]. The process is
184 also explained in **Supplementary Materials**.

185

186 **Immunocytochemistry Profiling of CTCs**

187 The process of ICC profiling of CTC was as described previously [26] and is also
188 provided in **Supplementary Materials**. A schema showing the various steps of the
189 process including CTC detection and ICC profiling is depicted in **Figure 1**. The
190 decision matrix for assigning samples as 'Positive', 'Equivocal' or 'Negative' based
191 on marker positivity and number of positive cells is provided in **Figure 2**. Samples
192 with equivocal findings were considered positive for the purpose of prostate cancer
193 detection by the test.

194

195 **Method Development and Optimization**

196 Comprehensive details of method development and optimization studies as well as
197 their findings are provided in the **Supplementary Materials**.

198

199 **Analytical Validation**

200 Analytical validations were performed by determining the recovery of reference
201 human prostate cancer cell line (VCaP) spiked into healthy donor blood samples.
202 VCaP reference cells were spiked at various densities as per the design of and
203 requirement for each validation parameter (specified in **Supplementary Materials**)
204 into healthy donor blood samples, which were processed as per the test for

205 enrichment of CTCs (spiked cells) and immunocytochemistry. The spike-recovery
206 study design was applicable for validation of analyte stability (and recovery),
207 linearity, limit of detection, limit of quantitation, limit of blank, sensitivity, specificity,
208 accuracy, precision and interference. Comprehensive details of study design,
209 observations and inferences are provided in **Supplementary Materials**.

210

211 **Case Control Clinical Study**

212 The ability of the Test to discern / identify PrAD from asymptomatic males was first
213 ascertained and established in a case control study with 160 males who were
214 recently diagnosed, therapy naïve cases of PrAD and 800 healthy males aged 49
215 years and above with no prior diagnosis of any cancer, no current suspicion of any
216 cancer and with serum PSA ≤ 0.5 ng / mL. Initially, samples in the Asymptomatic
217 cohort were randomized into Training, Test and Validation Sets in a 60%:20%:20%
218 ratio. The PrAD cases were first segregated by extent of disease as Localized
219 (confined to primary site), Regional (spread to regional lymph nodes) and Distant
220 (metastasized to distal lymph nodes or other organs) for which survival is known [2].
221 Subsequently, the samples were assigned to Training and Test Sets in a
222 60%:20%:20% ratio. The Training Set comprising of 96 PrAD and 480 healthy males'
223 samples was initially evaluated with the analysts unblinded to the status of the
224 samples. Next the blinded Test Set comprising of 32 PrAD and 160 healthy males'
225 samples was evaluated prior to blinded evaluation of the 32 PrAD and 160 healthy
226 males' samples in the Validation Set. Subsequently all Training, Test and Validation
227 set samples (PrAD and healthy) were shuffled and random 20% samples (extent-
228 wise for PrAD) were selected for analysis as Validation Set Iteration 2. This shuffling

229 step was repeated to obtain 20 iterations of the Validation Set from which median
230 and range of Sensitivity, Specificity and Accuracy were reported.

231

232 **Prospective Clinical Study**

233 The performance characteristics of the test was next ascertained and established in
234 a prospective clinical study of blood samples from 210 males with urological
235 symptoms who were suspected of PrAD based on either an enlarged prostate alone
236 (n = 80) or an enlarged prostate in conjunction with clinically suspicious or significant
237 (>3 ng / mL) serum PSA as determined by the Urologist (n = 130). All participants
238 provided 5 mL blood sample prior to undergoing a prostate biopsy. The findings of
239 the histopathological examination (HPE) and the final diagnosis (cancer or benign)
240 were initially blinded to the sponsor. Clinical status of samples (cancer / benign) was
241 revealed to sponsor only after sample analysis was complete and test findings
242 shared with the clinical study investigator to determine Sensitivity, Specificity and
243 Accuracy.

244

245 **Molecular Concordance Studies**

246 In a combined subset of 20 samples from the case-control and prospective cohorts,
247 where matched prostate cancer tumor tissue and blood samples were available, a
248 molecular concordance study was performed. Tumor Tissue DNA (ttDNA) was
249 isolated and profiled by Next Generation Sequencing (NGS) using the Ion Proton
250 Platform and the Oncomine Comprehensive Assay v3 Panel to identify gene variants
251 with loss of tumor suppression or gain of oncogenic function which have been
252 previously reported to be significant in / associated with prostate cancer.

253 Simultaneously, PBMCs were isolated from the matched blood samples and used for

254 CTC enrichment. On the fifth day, genomic DNA (gDNA) isolated from all surviving
255 cells was evaluated by a ddPCR assay specific to the detected gene variant on a
256 BioRad QX200 platform. Concordance between tumor tissue and CTCs was
257 determined as the proportion of the latter where the corresponding gene variant was
258 detected by ddPCR.

259 Tissue samples from the same 20 patients were also evaluated by fluorescence in
260 situ hybridization (FISH) as per manufacturer's protocol for TMPRSS2-ERG fusion.
261 In samples where tissue was positive for this variation, enriched and harvested
262 CTCs were also evaluated by FISH for the same biomarker.

263

264 **RESULTS**

265 **Method Development**

266 The method development studies showed the viability of multiplexed fluorescence
267 ICC for detection of PrAD CTCs even with significantly lower expression of EpCAM,
268 PanCK, AMACR and PSMA than primary tumor cells or reference cells
269 (**Supplementary Figure S1**), as well as other key aspects including specificity of
270 marker combination to prostate cancer (**Supplementary Figure S2**), absence of
271 PrAD CTCs in benign prostate conditions (**Supplementary Table S1**) and the ability
272 of the test to detect CTCs irrespective of patient age (**Supplementary Figure S3**),
273 PSA (**Supplementary Figure S4**) and Gleason Score (**Supplementary Figure S5**).
274 Comprehensive details are provided in **Supplementary Materials**.

275

276 **Analytical Validation**

277 **Table 1** is a summary of all the findings of the analytical validation study. Analytical
278 validation established analyte stability (**Supplementary Table S2-S3**), demonstrated

279 high sensitivity and specificity of the test (**Supplementary Table S4**), significant
280 linear characteristics (**Supplementary Figure S6**), high precision (**Supplementary**
281 **Table S5**) and no loss of sensitivity in presence of potentially interfering substances
282 (**Supplementary Table S6**). Comprehensive details are provided in **Supplementary**
283 **Materials**.

284

285 **Clinical Studies**

286 We evaluated the performance characteristics of the test in two clinical studies. The
287 demographic details of the study cohorts are provided in **Supplementary Table S7**.
288 Both studies were conducted in a South Asian cohort with <0.005% reported
289 prostate cancer incidence [29], and also where the prostate cancer risk in
290 asymptomatic males is significantly lower than the <7% reported among Caucasians
291 with ≤ 0.5 ng / mL serum PSA [30,31] most of whom are also expected to be
292 clinically insignificant prostate cancer [30,32]. Due to this low probability of an
293 underlying prostate cancer in healthy subjects, they were a suitable 'control'
294 population. Further, the selection of such a control population is also more ethical
295 since it would be unethical to perform a biopsy on asymptomatic individuals for the
296 sole purpose of ruling out prostate cancer for this study. The Case Control Study had
297 a stringent, blinded, iterative cross-validation design which minimized the risk of
298 overfitting. Detailed findings of the Training and Test Sets as well as the 20 iterations
299 of the Validation sets are provided in **Supplementary Table S8**). In this study, the
300 median sensitivity was 100% for local, regional and for metastatic disease as well as
301 overall (**Table 2**). In absence of any positive or equivocal findings in the control
302 (cancer free and asymptomatic) cohort, the specificity of the test (cancer v/s healthy)
303 was 100%.

304 In the second (prospective) clinical study with 210 symptomatic males, 68 (32.4%)
305 were eventually diagnosed with PrAD and 142 (67.6%) were diagnosed with various
306 benign prostate conditions. There were no positive or equivocal findings among
307 those diagnosed with benign prostate conditions. Hence the specificity of the test
308 (cancer v/s benign) was 100%. Among the 68 cancer cases, the Test assigned 56
309 samples as positive, 6 as equivocal and 6 as negative (**Supplementary Table S9**),
310 yielding a sensitivity of 91.2% since equivocals were considered as positive (**Table**
311 **2**). In the prospective study, the sensitivity of the test was observed to correlate
312 positively with Gleason Scores and PSA levels (where available) (**Supplementary**
313 **Table S10**).

314

315 **Molecular Concordance Studies**

316 Among the 20 tumor samples tested, driver mutations with allele frequency were
317 detected in 15 samples by NGS profiling of tumor tissue DNA using the Oncomine
318 Comprehensive Assay v3 Panel on the Ion Proton Platform. Among these 15 patient
319 samples, a specific TaqMan ddPCR assay was available for variants detected in 12
320 cases. CTC-enriched fraction from these samples were used for gDNA isolation
321 which in turn was evaluated by a ddPCR assay specific to the driver mutation on a
322 BioRad QX200 platform. Variants in ttDNA detected by NGS were also detected by
323 ddPCR in 9 (75%) CTCs (**Supplementary Table S11**). A subset of 4 PrAD cases
324 were identified where the tissue was positive for TMPRSS2-ERG fusion by FISH.
325 The CTC enriched fraction from these 4 samples was evaluated by FISH and the
326 TMPRSS2-ERG fusion was detected in 3 cases (75%). Overall, the orthogonal
327 concordance studies appeared to confirm that the CTCs detected by the Test

328 originated from the same prostate malignancy. The 75% concordance was
329 considered satisfactory in light of clonal diversity in tumor cells and CTCs.

330

331 **DISCUSSION**

332 We describe a blood test for Prostate cancer detection in asymptomatic males based
333 on multiplexed fluorescence ICC profiling of CTCs functionally enriched from a 5 mL
334 blood sample. The test can detect Prostate cancer irrespective of age, serum PSA
335 level and Gleason grade and also has high sensitivity regardless of the extent of
336 disease. Analytical validation ascertained accuracy and reliability of the test. The
337 case control cross-validation study demonstrated 100% median overall sensitivity
338 and 100.0% specificity for all stages of Prostate cancer. The subsequent prospective
339 clinical validation study demonstrated 91.2% Sensitivity and 100% Specificity in the
340 real world setting for detecting Prostate cancer and differentiating prostate cancer
341 from benign prostate conditions. The Test has (a) high sensitivity for all stages,
342 including early stages, (b) high specificity to minimize the risk of false positives, (c)
343 high positive predictive value, (d) high negative predictive value. The performance
344 characteristics of the test support its potential clinical utility in Prostate cancer
345 screening among asymptomatic males.

346 Presently, evaluation of serum PSA is part of standard prostate cancer diagnostic
347 work up in symptomatic men and is often evaluated as part of elective prostate
348 cancer screening in asymptomatic males [33,34]. However, PSA testing has lower
349 specificity and is associated with a high false positive rate, e.g. ~66% [5]. Other PSA-
350 based tests such as %-free PSA [35], [-2]pro-PSA (p2PSA) [36] and Prostate Health
351 Index (PHI) [37] with documented sensitivity / specificity trade-off [35,38,39] are
352 currently not recommended or approved for routine prostate cancer screening. The

353 inverse relationship between specificity and sensitivity of PSA and PSA based tests
354 [39] implies inefficient triaging where a significant proportion of individuals who do
355 undergo a prostate biopsy based on these tests may actually be free from prostate
356 cancer. Based on the limitations of serum PSA evaluations alone to provide
357 meaningful insight into prostate cancer detection, Thompson et al suggested that
358 *'PSA levels should no longer be referred to as 'normal' or 'elevated' but should be*
359 *incorporated into a multivariable risk assessment to provide individualized risk*
360 *information for decision making'*[40]. Among other non-invasive (blood-based)
361 approaches, a pan-cancer detection test based on methylation profiling in cfDNA
362 reported very low sensitivity (~10%) for localized Prostate cancer [41,42].
363 Our test is based on detection of CTCs, which are ubiquitous in blood of patients
364 with an underlying solid organ cancer [28] and unlikely in the blood of individuals
365 without an underlying malignancy as well as those with other non-malignant or
366 inflammatory conditions. CTCs are hence an ideal analyte to differentiate individuals
367 with and without an underlying malignant condition with high specificity and
368 sensitivity. There appear to be limited or no risks associated with use of the test
369 since it is non- (or minimally) invasive and is performed on a venous draw of 5 mL
370 peripheral blood. The potential benefits of the test include detection of Prostate
371 cancer at early (localized) stages. The strengths of our study include (a) use of
372 adequately powered sample sizes, (b) sample blinding to eliminate bias, (c) an
373 iterative cross-validation design intended to eliminate risk of cross fitting, and (d) a
374 prospective study in a real-world setting. The analytical and clinical validations
375 described in this manuscript provide tangible evidence of the test performance which
376 supports the hypothesis (design) as well as the intended use of the test. The high
377 specificity translates into an exceedingly low risk of false positives in individuals with

378 benign prostate conditions which eliminates or significantly reduces risks of
379 overdiagnosis or overtreatment in these individuals.

380 Although the test has high performance characteristics for Prostate cancer detection,
381 we note the following potential limitations of the test. Non-(adeno)-carcinoma types
382 which account for <8% of Prostate cancer are not detected by this test. The
383 sensitivity for the detection was lower for localized Prostate cancer in the prospective
384 study (at ~75%). We speculate that the false negative cases could be attributed to
385 biologically different characteristics of some Prostate cancers. However, these false
386 negatives would not add to the pre-existing risk of the individual since the risk of
387 missing localized cancers can be partially mitigated by the higher sensitivity for
388 subsequent detection at regional stages with comparable 5-year survival.

389 While the risk stratification of prostate cancer includes serum PSA level, clinical
390 stage and Gleason score, a Gleason score of >8 is considered an independent
391 predictor of high-risk disease with increased rates of treatment failures and poorer
392 outcomes. Our test is not intended to provide information on, or correlate with, the
393 Gleason score. Our test has high sensitivity for detection of high-grade / aggressive
394 prostate cancers which require urgent multi-modality treatment approaches and
395 where early detection is vital for more effective clinical management. There would
396 appear to be a minimal risk of overdiagnosis from detection of low-grade (lower risk)
397 prostate cancers which account for up to 66% of all prostate cancers [43]. However,
398 since up to 40% of patients initially diagnosed with low-risk prostate cancer
399 demonstrate pathological progression over time [44], detection of low-grade prostate
400 cancers can benefit from active surveillance [45].

401

402 **CONCLUSION:**

403 The high sensitivity and specificity of the test enables prostate cancer detection and
404 differentiation from benign prostate conditions (or healthy individuals) and presents
405 significant advantages over PSA based approaches. The test has potential to reduce
406 the need for invasive biopsies and thus significantly mitigates risks of overdiagnosis
407 and overtreatment. The potential benefits of the test are compelling and support the
408 need for further prospective large cohort clinical studies to determine the
409 performance characteristics of the test for detection of prostate cancer, especially
410 localized disease.

411

412 **ADDITIONAL INFORMATION**

413

414 **ACKNOWLEDGEMENTS**

415 The authors are grateful to the staff of the Study Sponsor (DCG) for their contributions
416 in managing various clinical, operational and laboratory aspects of the study.

417

418 **ETHICS APPROVAL AND CONSENT TO PARTICIPATE**

419 All biological samples were obtained from participants in three studies,
420 TRUEBLOOD (<http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31879>), ProState
421 (<http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31713>) and RESOLUTE
422 (<http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30733>). All studies were
423 approved by Datar Cancer Genetics Limited Institutional Ethics Committee. All
424 participants provided written informed consent. All studies were performed in
425 accordance with the Declaration of Helsinki.

426

427 **DATA AVAILABILITY**

428 All relevant data are included in the manuscript and its Supplementary Information
429 file.

430 **FUNDING**

431 No external funding was obtained for this study. The entire study was funded by the
432 Study Sponsor (DCG).

433

434 **REFERENCES**

- 435 [1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.
436 Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and
437 Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*
438 2021;71:209–49. <https://doi.org/10.3322/caac.21660>.
- 439 [2] Cancer Stat Facts: Prostate Cancer. Natl Cancer Inst Surveillance, Epidemiol
440 End Results Progr n.d. <https://seer.cancer.gov/statfacts/html/prost.html>
441 (accessed April 9, 2022).
- 442 [3] Prostate-Specific Antigen (PSA) Test. Natl Cancer Inst n.d.
443 <https://www.cancer.gov/types/prostate/psa-fact-sheet/> (accessed November
444 16, 2021).
- 445 [4] Holmström B, Johansson M, Bergh A, Stenman U-H, Hallmans G, Stattin P.
446 Prostate specific antigen for early detection of prostate cancer: longitudinal
447 study. *BMJ* 2009;339:b3537. <https://doi.org/10.1136/bmj.b3537>.
- 448 [5] Kilpeläinen TP, Tammela TLJ, Roobol M, Hugosson J, Ciatto S, Nelen V, et al.
449 False-positive screening results in the European randomized study of
450 screening for prostate cancer. *Eur J Cancer* 2011;47:2698–705.
451 <https://doi.org/10.1016/j.ejca.2011.06.055>.
- 452 [6] Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, et al.
453 Overdiagnosis and overtreatment of prostate cancer. *Eur Urol* 2014;65:1046–

- 454 55. <https://doi.org/10.1016/j.eururo.2013.12.062>.
- 455 [7] Mahal BA, Aizer AA, Efstathiou JA, Nguyen PL. Association of very low
456 prostate-specific antigen levels with increased cancer-specific death in men
457 with high-grade prostate cancer. *Cancer* 2016;122:78–83.
458 <https://doi.org/10.1002/cncr.29691>.
- 459 [8] D’Amico A V, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA,
460 et al. Biochemical outcome after radical prostatectomy, external beam
461 radiation therapy, or interstitial radiation therapy for clinically localized prostate
462 cancer. *JAMA* 1998;280:969–74. <https://doi.org/10.1001/jama.280.11.969>.
- 463 [9] Campos-Fernández E, Barcelos LS, de Souza AG, Goulart LR, Alonso-Goulart
464 V. Research landscape of liquid biopsies in prostate cancer. *Am J Cancer Res*
465 2019;9:1309–28.
- 466 [10] Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ,
467 Whitlock NC, et al. Low Abundance of Circulating Tumor DNA in Localized
468 Prostate Cancer. *JCO Precis Oncol* 2019;3.
469 <https://doi.org/10.1200/PO.19.00176>.
- 470 [11] Labib M, Kelley SO. Circulating tumor cell profiling for precision oncology. *Mol*
471 *Oncol* 2021;15:1622–46. <https://doi.org/10.1002/1878-0261.12901>.
- 472 [12] van der Toom EE, Verdone JE, Pienta KJ. Disseminated tumor cells and
473 dormancy in prostate cancer metastasis. *Curr Opin Biotechnol* 2016;40:9–15.
474 <https://doi.org/10.1016/j.copbio.2016.02.002>.
- 475 [13] Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, et al.
476 Disseminated tumor cells in prostate cancer patients after radical

- 477 prostatectomy and without evidence of disease predicts biochemical
478 recurrence. Clin Cancer Res an Off J Am Assoc Cancer Res 2009;15:677–
479 83. <https://doi.org/10.1158/1078-0432.CCR-08-1754>.
- 480 [14] Fizazi K, Morat L, Chauveinc L, Prapotnich D, De Crevoisier R, Escudier B, et
481 al. High detection rate of circulating tumor cells in blood of patients with
482 prostate cancer using telomerase activity. Ann Oncol Off J Eur Soc Med
483 Oncol 2007;18:518–21. <https://doi.org/10.1093/annonc/mdl419>.
- 484 [15] Ried K, Tamanna T, Matthews S, Eng P, Sali A. New Screening Test Improves
485 Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-
486 Specific Markers. Front Oncol 2020;10:582.
487 <https://doi.org/10.3389/fonc.2020.00582>.
- 488 [16] Kuske A, Gorges TM, Tennstedt P, Tiebel A-K, Pompe R, Preißer F, et al.
489 Improved detection of circulating tumor cells in non-metastatic high-risk
490 prostate cancer patients. Sci Rep 2016;6:39736.
491 <https://doi.org/10.1038/srep39736>.
- 492 [17] Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, et al. Isolation and
493 characterization of circulating tumor cells from patients with localized and
494 metastatic prostate cancer. Sci Transl Med 2010;2:25ra23.
495 <https://doi.org/10.1126/scitranslmed.3000403>.
- 496 [18] Shao C, Liao C-P, Hu P, Chu C-Y, Zhang L, Bui MHT, et al. Detection of live
497 circulating tumor cells by a class of near-infrared heptamethine carbocyanine
498 dyes in patients with localized and metastatic prostate cancer. PLoS One
499 2014;9:e88967. <https://doi.org/10.1371/journal.pone.0088967>.
- 500 [19] Spizzo G, Fong D, Wurm M, Ensinger C, Obrist P, Hofer C, et al. EpCAM

- 501 expression in primary tumour tissues and metastases: an
502 immunohistochemical analysis. *J Clin Pathol* 2011;64:415–20.
503 <https://doi.org/10.1136/jcp.2011.090274>.
- 504 [20] Rao CG, Chianese D, Doyle G V, Miller MC, Russell T, Sanders RAJ, et al.
505 Expression of epithelial cell adhesion molecule in carcinoma cells present in
506 blood and primary and metastatic tumors. *Int J Oncol* 2005;27:49–57.
- 507 [21] de Wit S, Manicone M, Rossi E, Lampignano R, Yang L, Zill B, et al.
508 EpCAM(high) and EpCAM(low) circulating tumor cells in metastatic prostate
509 and breast cancer patients. *Oncotarget* 2018;9:35705–16.
510 <https://doi.org/10.18632/oncotarget.26298>.
- 511 [22] Adams DL, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri
512 S, et al. Cytometric characterization of circulating tumor cells captured by
513 microfiltration and their correlation to the CellSearch(®) CTC test. *Cytometry*
514 *A* 2015;87:137–44. <https://doi.org/10.1002/cyto.a.22613>.
- 515 [23] Sheng Y, Wang T, Li H, Zhang Z, Chen J, He C, et al. Comparison of analytic
516 performances of Cellsearch and iFISH approach in detecting circulating tumor
517 cells. *Oncotarget* 2017;8:8801–6. <https://doi.org/10.18632/oncotarget.6688>.
- 518 [24] Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical
519 impact and future directions. *Cancer Lett* 2007;253:180–204.
520 <https://doi.org/10.1016/j.canlet.2006.12.014>.
- 521 [25] Crook T, Gaya A, Page R, Limaye S, Ranade A, Bhatt A, et al. Clinical utility of
522 circulating tumor-associated cells to predict and monitor chemo-response in
523 solid tumors. *Cancer Chemother Pharmacol* 2021;87:197–205.
524 <https://doi.org/10.1007/s00280-020-04189-8>.

- 525 [26] Gaya A, Crook T, Plowman N, Ranade A, Limaye S, Bhatt A, et al. Evaluation
526 of circulating tumor cell clusters for pan-cancer noninvasive diagnostic
527 triaging. *Cancer Cytopathol* 2021;129:226–38.
528 <https://doi.org/10.1002/cncy.22366>.
- 529 [27] Iczkowski KA. Adenocarcinoma. *PathologyOutlinesCom* n.d.
530 <https://www.pathologyoutlines.com/topic/prostateadenoNOS.html> (accessed
531 November 15, 2021).
- 532 [28] Akolkar D, Patil D, Crook T, Limaye S, Page R, Datta V, et al. Circulating
533 ensembles of tumor-associated cells: A redoubtable new systemic hallmark of
534 cancer. *Int J Cancer* 2020;146:3485–94. <https://doi.org/10.1002/ijc.32815>.
- 535 [29] Cancer Today: Population Fact Sheets. *Glob Cancer Obs* n.d.
536 <https://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf>
537 (accessed May 9, 2022).
- 538 [30] Carter HB. Prostate cancers in men with low PSA levels--must we find them?
539 *N Engl J Med* 2004;350:2292–4. <https://doi.org/10.1056/NEJMe048003>.
- 540 [31] Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et
541 al. Prevalence of prostate cancer among men with a prostate-specific antigen
542 level < or =4.0 ng per milliliter. *N Engl J Med* 2004;350:2239–46.
543 <https://doi.org/10.1056/NEJMoa031918>.
- 544 [32] McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey
545 TA. Patterns of progression in prostate cancer. *Lancet* (London, England)
546 1986;1:60–3. [https://doi.org/10.1016/s0140-6736\(86\)90715-4](https://doi.org/10.1016/s0140-6736(86)90715-4).
- 547 [33] Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB,

- 548 Davidson KW, et al. Screening for Prostate Cancer: US Preventive Services
549 Task Force Recommendation Statement. JAMA 2018;319:1901–13.
550 <https://doi.org/10.1001/jama.2018.3710>.
- 551 [34] PSA Testing: Prostate Cancer. Natl Heal Serv (NHS), UK n.d.
552 <https://www.nhs.uk/conditions/prostate-cancer/psa-testing/> (accessed
553 November 16, 2021).
- 554 [35] Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al.
555 Use of the percentage of free prostate-specific antigen to enhance
556 differentiation of prostate cancer from benign prostatic disease: a prospective
557 multicenter clinical trial. JAMA 1998;279:1542–7.
558 <https://doi.org/10.1001/jama.279.19.1542>.
- 559 [36] Abrate A, Lughezzani G, Gadda GM, Lista G, Kinzikeeva E, Fossati N, et al.
560 Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate
561 Health Index) for the detection of prostate cancer: a review of the literature.
562 Korean J Urol 2014;55:436–45. <https://doi.org/10.4111/kju.2014.55.7.436>.
- 563 [37] Loeb S, Catalona WJ. The Prostate Health Index: a new test for the detection
564 of prostate cancer. Ther Adv Urol 2014;6:74–7.
565 <https://doi.org/10.1177/1756287213513488>.
- 566 [38] Wolf AMD, Wender RC, Etzioni RB, Thompson IM, D’Amico A V, Volk RJ, et
567 al. American Cancer Society guideline for the early detection of prostate
568 cancer: update 2010. CA Cancer J Clin 2010;60:70–98.
569 <https://doi.org/10.3322/caac.20066>.
- 570 [39] Fuchsova R, Topolcan O, Windrichova J, Hora M, Dolejsova O, Pecen L, et al.
571 PHI in the Early Detection of Prostate Cancer. Anticancer Res 2015;35:4855–

- 572 7.
- 573 [40] Thompson IMJ, Leach RJ, Ankerst DP. Focusing PSA testing on detection of
574 high-risk prostate cancers by incorporating patient preferences into decision
575 making. *JAMA* 2014;312:995–6. <https://doi.org/10.1001/jama.2014.9680>.
- 576 [41] Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden M V. Sensitive and specific
577 multi-cancer detection and localization using methylation signatures in cell-
578 free DNA. *Ann Oncol Off J Eur Soc Med Oncol* 2020;31:745–59.
579 <https://doi.org/10.1016/j.annonc.2020.02.011>.
- 580 [42] Klein EA, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D, et al.
581 Clinical validation of a targeted methylation-based multi-cancer early detection
582 test using an independent validation set. *Ann Oncol Off J Eur Soc Med Oncol*
583 2021;32:1167–77. <https://doi.org/10.1016/j.annonc.2021.05.806>.
- 584 [43] Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade
585 grouping: data based on the modified Gleason scoring system. *BJU Int*
586 2013;111:753–60. <https://doi.org/10.1111/j.1464-410X.2012.11611.x>.
- 587 [44] Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of
588 long-term follow-up of a large, active surveillance cohort with localized
589 prostate cancer. *J Clin Oncol Off J Am Soc Clin Oncol* 2010;28:126–31.
590 <https://doi.org/10.1200/JCO.2009.24.2180>.
- 591 [45] Preston MA, Feldman AS, Coen JJ, McDougal WS, Smith MR, Paly JJ, et al.
592 Active surveillance for low-risk prostate cancer: Need for intervention and
593 survival at 10 years. *Urol Oncol* 2015;33:383.e9-16.
594 <https://doi.org/10.1016/j.urolonc.2015.04.015>.

596 **LIST OF FIGURES**

597 **Figure 1. Schema of Test.**

598 Functional enrichment of CTCs is achieved using a proprietary CTC enrichment
599 medium (CEM) that eliminates all non-malignant cells and permits tumor derived
600 malignant cells to survive. Subsequently, the multiplexed immunocytochemistry
601 (ICC) evaluates and identifies PrAD-CTCs based on positivity of the indicated
602 markers.

603

604 **Figure 2. Decision Matrix for Classifying Samples.**

605 The detection threshold for PrAD-CTCs is ≥ 15 PanCK cells / 5 mL, which is
606 constituted by the detection of ≥ 5 PSMA+ cells, ≥ 5 AMACR+ cells and ≥ 5 EpCAM+
607 cells in the respective aliquots. Priority is given to PSMA and AMACR over EpCAM
608 while classifying samples as '**Positive**' to ensure specificity for PrAD over other
609 epithelial malignancies where EpCAM+ cells may be detected.

610

611

612

613 **LIST OF TABLES**

614 **Table 1. Findings of Analytical Validation Studies.**

615 The summary of findings of the Analytical Validation Studies indicate that the Test
616 provides consistent, accurate and reproducible results with little or no interference
617 from routine endogenous or exogenous factors when samples are obtained, stored
618 and processed under the recommended conditions.

619

620 **Table 2. Findings of Clinical Validation Studies.**


621 The table provides the Stage-wise and overall performance characteristics of the
622 Test which were determined from 20 iterations of the Validation Set. Values within
623 parentheses indicate 95% Confidence intervals.

624

625

626

627 **Figure 1. Schema of Test.**




628

629

630

631 **Figure 2. Decision Matrix for Classifying Samples.**

632



633

634

Table 1. Findings of Analytical Validation Studies.

	EpCAM, PanCK, CD45	PSMA, PanCK, CD45	AMACR, PanCK, CD45	Overall
Analyte Stability	48h			
Recovery¹	97.2%	94.4%	94.4%	91.7%
Limit of detection	< 1 cell / mL			
Linear Range	1-256 cells / mL			
Linearity	R ² ≥ 0.99	R ² ≥ 0.99	R ² ≥ 0.99	R ² ≥ 0.99
Sensitivity	95.0%	92.5%	92.5%	92.5%
Specificity	100.0%	100.0%	100.0%	100.0%
Accuracy	97.1%	95.7%	95.7%	95.7%
Precision	CV ≤ 9%	CV ≤ 6%	CV ≤ 6%	CV ≤ 9%
Robustness	CV < 10%			
¹ Above 10 cells / 5 mL as determined from the Linearity experiment. Values within parentheses represent 95% CI.				

Table 2. Findings of Clinical Validation Studies.

	Case Control Study, Cancer v/s Asymptomatic <i>Specificity: 100.0% (95% CI: 97.7% - 100.0%)</i>		Prospective Study, Cancer vs Benign <i>Specificity: 100.0% (95% CI: 97.4% - 100.0%)</i>	
	Sensitivity	Accuracy	Sensitivity	Accuracy
Cumulative	100.0% <i>95%CI: 89.1% - 100.0%</i>	100.0% <i>95%CI: 98.1% - 100.0%</i>	91.2% <i>95%CI: 81.8% - 96.7%</i>	97.14% <i>95%CI: 93.9% - 98.9%</i>
<i>Local</i>	100.0% <i>95%CI: 79.4% - 100.0%</i>	100.0% <i>95%CI: 97.9% - 100.0%</i>	75.0% <i>95%CI: 50.9% to 91.3%</i>	96.9% <i>95%CI: 92.9% - 98.9%</i>
<i>Regional</i>	100.0% <i>95%CI: 97.7% - 100.0%</i>	100.0% <i>95%CI: 97.8% - 100.0%</i>	85.7% <i>95%CI: 42.1% - 99.6%</i>	99.3% <i>95%CI: 96.3% - 99.9%</i>
<i>Distal</i>	100.0% <i>95%CI: 97.7% - 100.0%</i>	100.0% <i>95%CI: 97.8% - 100.0%</i>	100.0% <i>95%CI: 90.8% - 100.0%</i>	100.0% <i>95%CI: 97.9% - 100.0%</i>